Patients receiving B-cell-depleting therapies (BCDT) are at an increased risk for severe COVID-19. Passive antibody therapy (PAT). including COVID-19 convalescent plasma (CCP) and monoclonal antibodies (mAb). may be an effective treatment in this population. https://www.ealisboa.com/limited-price-Cable-Splitter-weBoost-WilsonPro-by-Wilson-Electronics-mega-offer/